Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosis.
Marcus M MückeMaría Hernández-TejeroWenyi GuMichael KuhnMalte JanzMarisa I KellerAnthony FullamLaura AltepeterVictoria T MückeFabian FinkelmeierKatharina M SchwarzkopfCarla CremonesePeter-Merton HunyadyMyriam W HeilaniFrank Erhard UschnerRobert SchierwagenMaximilian J BrolJulia FischerSabine KleinKai-Henrik PeifferMichael HogardtSaeed ShoaieMinneke J CoenraadJörg BojungaVicente ArroyoStefan ZeuzemVolkhard A J KempfChristoph WelschWim LalemanPeer BorkJavier FernandezJonel Trebickanull nullPublished in: Alimentary pharmacology & therapeutics (2024)
Our study reports an increased risk of MDRO colonisation in patients with AD or ACLF, who recently received terlipressin therapy, while other commonly prescribed non-antibiotic co-medications had negligible influence. Future prospective trials are needed to confirm these results.